COLLABORATION AGREEMENT by and between SURFACE ONCOLOGY, INC. and NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.Collaboration Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of January 9, 2016 (the “Effective Date”), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Surface”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Novartis”). Surface and Novartis are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Amendment to and Waiver under Exclusive License and Commercialization AgreementCommercialization Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This Amendment to and Waiver under the Exclusive License and Commercialization Agreement (this “Amendment”) is made and entered into as of October 25, 2023, by and between Shanghai Junshi Biosciences Co., Ltd. (“Junshi”) and Coherus BioSciences, Inc. (“Coherus”). Each of Junshi and Coherus is sometimes referred to herein, individually, as a “Party” and, collectively as the “Parties.”
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment No. 1”) to the License Agreement dated December 20, 2020 between GlaxoSmithKline Intellectual Property (No. 4) Limited, having a principal place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (“GSK”) and Surface Oncology, Inc., having a place of business at 50 Hampshire Street, Cambridge MA 02139 (“Surface”) is effective as of August 11, 2021 (“Amendment Effective Date”). Each of GSK and Surface may be referred to herein as a “Party” and together, the “Parties”.
FIRST AMENDED AND RESTATED DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This First Amended and Restated Development and Option Agreement (this “Agreement”) made effective as of October 3, 2018 (the “Amended Effective Date”), is entered into by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (“Surface”).
Exclusive Product License AgreementExclusive Product License Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive Product License Agreement (this “Agreement”) is made and entered into as of this 23rd day of March, 2021 (the “Effective Date”) by and between Vaccinex, Inc., having offices at 1895 Mt. Hope Avenue, Rochester NY 14620 USA (“Vaccinex”), and Surface Oncology, Inc. having offices at 50 Hampshire St, 8th Floor, Cambridge, MA 02139 (“Surface”). Vaccinex and Surface are sometimes referred to herein each individually as a “Party” and collectively as the “Parties.”
Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. SIXTH AMENDMENTCoherus BioSciences, Inc. • March 15th, 2024 • Biological products, (no disgnostic substances)
THIS SIXTH AMENDMENT (this “Amendment”) is made and entered into as of October 24, 2023, by and between HUDSON 333 TWIN DOLPHIN PLAZA, LLC, a Delaware limited liability company (“Landlord”), and COHERUS BIOSCIENCES, INC., a Delaware corporation (“Tenant”).
LICENSE AGREEMENTLicense Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (this “Agreement”), is entered into as of December 16, 2020 (the “Effective Date”), by and between Surface Oncology, Inc., a Delaware corporation having business offices at 50 Hampshire Street, Cambridge MA 02139 (“Surface”), and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (“GSK”).
Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.Coherus BioSciences, Inc. • March 15th, 2024 • Biological products, (no disgnostic substances) • California
Your resignation from the position as Chief Financial Officer will be effective December 31, 2023 (the “Separation Date”). This letter (the “Agreement”) provides information regarding the mutual separation package agreement offered to you by Coherus Biosciences, Inc. (the “Company”) should you agree to sign this Agreement.
FOURTH AMENDMENT TO COLLABORATION AGREEMENTCollaboration Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This Fourth Amendment (the “Fourth Amendment”) to the Agreement (as defined below), is entered into as of October 9, 2018 (the “Amendment Effective Date”), by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Surface”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Novartis”).
